Scottd Barnes News Today

In March 2022, the U.S. Food and Drug Administration (FDA) granted approval of the EVO/EVO+ Visian Implantable Collamer Lens (EVO) for the correction of myopia and myopia with astigmatism. Myopia is also known as nearsightedness or the need for distance vision correction.

LAKE FOREST, Calif.--(BUSINESS WIRE)--Mar 28, 2022--

Staar Surgical (Nasdaq:STAA) announced today that it received FDA approval for its Evo/Evo+ Visian implantable Collamer lens.

The FDA approved the EVO/EVO+ Visian implantable Collamer lens for the correction of myopia and myopia with astigmatism, according to a press release from STAAR Surgical.The EVO lenses are implanted in the posterior chamber, behind the iris and in front of the patient’s natural crystalline lens. A preoperative peripheral iridotomy, which was required with earlier versions of the Visian ICL,